• Blog
  • Budesonide Market Report

    Budesonide Market Report

    Budesonide Market Report
    Report code - SR1097 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Budesonide Market, Dynamics, Trends, Market Insights
    See more...

    Impact of COVID-19 on Budesonide Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Budesonide Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Budesonide Market is estimated to grow from USD xx million in 2020 to USD xx million by 2026 at a healthy CAGR of xx% during the forecast period.

    Figure: Budesonide Market Size, 2020-2026 (USD Million)

    Budesonide-Market-Forecast

    Wish to get a free sample report? Click here.

    What is Budesonide?

    Budesonide is primarily used to prevent and control symptoms such as shortness and wheezing of breath caused by asthma. It belongs to a class of drugs known as corticosteroids. It mainly works directly to the lungs to make breathing easier by reducing the swelling and irritation of the airways. Budesonide is sold under the brand name Pulmicort, which is a steroid medication.

    Key Players

    Key players operating in the budesonide market are-

    • AstraZeneca (UK),
    • Teva (Israel),
    • Mylan (The U.S),
    • Sandoz (Switzerland),
    • Cosmo Pharmaceuticals (Ireland),
    • Salix (The U.S),
    • Chiesi Farmaceutici (Italy),
    • Orion Corporation (Finland),
    • Cipla (India), and
    • Synmosa Biopharma (Taiwan).

    Market Dynamics

    The rising prevalence of asthma around the globe, strong growth in healthcare infrastructure, the surge in the diagnosis and treatment rate of asthma, and favourable reimbursement policies are some of the key factors augmenting the industry growth.

    In addition, the strong emergence of generic companies, expiry of patented drugs, growing R&D investment, and technological development in the medical industry are expected to offer growth opportunities during the review period.

    Segments' Analysis

    Application Trends

    Based on application, the Budesonide market is classified into respiratory disease treatment, nose disease treatment, inflammatory bowel disease treatment, and others.

    • The respiratory disease treatment segment held a significant share in 2020 and is projected to grow at the highest CAGR during the assessment period.
    • Budesonide is widely used in long-term management of asthma and chronic obstructive pulmonary disease (COPD). Rising respiratory diseases further bolsters the segment growth.

    Regional Trends

    By region, the Asia Pacific market accounted for the largest share in 2020 and is expected to grow at a substantial CAGR in the following years.

    • This is mainly ascribed to the growing population as well as rising air pollution in the region especially in the countries such as India and China.
    • Moreover, China is expected to dominate the budesonide market in the near future due to increasing cases of respiratory illness in the country, which further proliferates the regional market growth.

    COVID-19 Impact on Budesonide Market

    The COVID-19 outbreak has moderately affected the budesonide industry. Due to stringent lockdown and social distance norms, there are limited production activities and a limited supply of raw material supply. Limited workforce and shutdown of operations are further affected by the industry growth. However, rising respiratory illness during the pandemic is expected to create a demand for budesonide, thus driving the industry's growth.

    Critical Questions Answered in the Report

    • What are the key trends in the budesonide market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the budesonide market?
    • What are the key strategies adopted by the major vendors to lead in the budesonide market?
    • What is the market share of the top vendors?

    Target Audience

    Here is the list of the group of customers that the Budesonide market hopes to have the greatest opportunity to convert-

    • Budesonide vendors
    • Budesonide retailers
    • Pharmaceutical companies
    • Hospitals

    Wish to know more about the study? Click here

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected]

    Frequently Asked Questions (FAQs)

    AstraZeneca (UK), Teva (Israel), Mylan (The U.S), Sandoz (Switzerland), Cosmo Pharmaceuticals (Ireland), Salix (The U.S), Chiesi Farmaceutici (Italy), Orion Corporation (Finland), Cipla (India) and Synmosa Biopharma (Taiwan) are among the key players in the budesonide market.

    Asia Pacific market accounted for the largest share in 2020 and is expected to grow at a substantial CAGR.

    China is expected to dominate the budesonide market in Asia-pacific region in the coming years.

    The respiratory disease treatment segment is expected to grow at the highest CAGR in the budesonide market during the forecast period.

    The rising prevalence of asthma around the globe, strong growth in healthcare infrastructure, the surge in the diagnosis and treatment rate of asthma, and favourable reimbursement policies are the factors driving the growth of budesonide market.

    Budesonide vendors, Budesonide retailers, Pharmaceutical companies, Hospitals are the target audience in the budesonide market.

    •